Evaluation
*
Strongly disagreeDisagreeSlightly disagreeNeitherSlightly agreeAgreeStrongly agree
The activity presented balanced, evidence-based content free of commercial bias.
The presenter(s) used an effective teaching strategy.
The presentation slides / digital materials / resources and handouts were high quality.
The content was relevant to / useful for my professional practice.
The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care.
The overall quality of the educational activity was excellent.
*
Strongly disagreeDisagreeSlightly disagreeNeitherSlightly agreeAgreeStrongly agree
Describe the context and need for advanced training in medical management of CBRN casualties.
Apply the CRESS algorithm to identify toxidromes (consciousness, respirations, eyes, secretions, skin).
Identify opportunities to treat chemical, biological, radiological, and nuclear (CBRN) casualties through the LADMER (liberation, absorption, distribution, metabolism, elimination, response) approach.
Recognize useful reference materials for management of CBRN casualties.
Describe nerve agent pathophysiology from molecular to patient level.
Manage nerve agent casualties at the Role 3/4, and intensive care setting.
Recognize novel and contingency treatments for cholinergic crisis.
Integrate NATO-Ally formularies to manage nerve agent casualties.
Prepare for management of multiple simultaneous severe nerve agent casualties.
Describe fundamental principles for identifying and treating a casualty with a metabolic agent intoxication.
Describe the pharmacokinetic properties of naloxone, including its absorption, distribution, metabolism, and elimination.
Identify an appropriate antidote for a person poisoned with thallium or arsenic describing its mechanism of action and administration protocol.
Select the appropriate pharmacological agent to manage agitation, autonomic activity, and prevent or treat seizures, given a case involving a patient exposed to anticholinergic agents.
Describe the importance of and initial formation of the Department of Defense (DoD) and Food and Drug Administration’s (FDA’s) Shelf-Life Extension Program (SLEP).
Summarize eligibility requirements for enrolling medications into SLEP.
Outline chemical treatment considerations for chemical and nerve agent exposures.
Identify inventory considerations and potential use rates when responding to a chemical attack.
Compare USCENTCOM’s informal SLEP program to the DoD’s SLEP program.
Identify the clinical effects and rates of recovery of pulmonary agents and vesicants.
Summarize the pharmacological therapies used to manage patients exposed to pulmonary agents and vesicants.
Given a patient case, select the agent used and appropriate treatment based on exposure history and symptoms.
*
*
*
*
*
*
*